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Epigenetic regulators represent a new class of therapeutic
targets for cancer [1]. Substantial studies suggest that the
enhancer of zeste homolog 2 (EZH2) is one of such pro-
mising targets [2-4]. The current model of EZH2 onco-
genic activity primarily focuses on its function as a
subunit of Polycomb repressive complex 2 (PRC2), which
silences gene expression via EZH2 histone methyltrans-
ferase activity [5,6].
Using a genome-wide approach we found that the onco-
genic function of EZH2 in castration resistant prostate
cancer (CRPC) is independent of its role as a transcrip-
tional repressor. Instead, it involves the ability of EZH2 to
act as a co-activator for critical transcription factors
including the androgen receptor (AR). This functional
switch is dependent on phosphorylation of EZH2, and
requires an intact methyltransferase domain. Given that
the loss-of-function mutations of EZH2 were observed in
myelodysplastic syndrome and acute leukemia [7,8], our
discovery of the non-PRC2 function of EZH2 in CRPC
raises the potential to develop inhibitors that specifically
target the EZH2 activation function while sparing its
PRC2 repressive function to avoid the potential hematolo-
gic side effects. In addition, our finding that EZH2 coop-
erates with AR-associated complexes and requires
phosphorylation to support CRPC growth suggests novel
combination therapies for the treatment of metastatic,
hormone-refractory prostate cancer.
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